Timothy Squire is Co-Chair of the firm’s International Life Sciences Industry Group. Bringing extensive regulatory and commercialization experience, Tim is a trusted advisor to both large and small drug, device, natural health product, cosmetic and food manufacturers.
Tim’s practice is devoted to the Life Sciences industry. He adds substantial bench strength to the firm's Life Sciences Group given his extensive knowledge and experience across the entire health product lifecycle. Tim has become a trusted advisor to many many stakeholders in the drug, device, natural health product, cosmetic and food industries in Canada and around the world due to his expertise and commitment to client service.
Tim's regulatory practice covers all aspects of health product regulation, and he is one of the few specialists in Canada regularly called upon to help solve complex health product compliance and enforcement issues. To this end, Tim frequently communicates with Health Canada and other federal and provincial regulators on our clients’ behalf.
In addition to his regulatory expertise, Tim also negotiates and drafts sophisticated commercial arrangements for Life Sciences clients, including license agreements, distribution agreements, manufacturing and supply agreements, technology and material transfer agreements, joint R&D agreements, and funding agreements.
Tim also quarterbacks regulatory due diligence in complex domestic and cross-border transactions involving drug, medical device, natural health product, cosmetic, and food companies, and is often called upon to manage the transition of market authorizations and regulatory operations post acquisition.
Tim performs in-house legal functions for several U.S. and international clients without Canadian in-house legal or regulatory capabilities, and in this capacity has developed a comprehensive understanding of the business issues and pressures facing companies in the life sciences industry.
Tim’s expertise in the life sciences sector has been recognized by Chambers Canada, Who’s Who Legal, IAM Strategy 300: The World’s Leading IP Strategists, and he has twice received LMG’s Life Sciences Canadian Regulatory Attorney of the Year award.